Hyderabad, India-based Dr. Reddy’s Laboratories Ltd., and Prestige BioPharma Ltd., a Singapore-based firm, entered into an exclusive partnership for the supply and commercialization of the latter’s proposed Trastuzumab biosimilar, in select countries.
Trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer, a regulatory filing from India’s drug maker said.
Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is over expressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells.
Lisa S. Park, CEO of Prestige BioPharma, commented, “With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets.
M.V. Ramana, CEO, Branded Markets at Dr.Reddy’s, said, “In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients.”
Last updated: December 26th, 2025
